Relay Therapeutics Stock Surges to New 52-Week High After Analyst Upgrade

Guggenheim raises price target on the biotech company's shares

Mar. 13, 2026 at 2:50pm

Got story updates? Submit your updates here. ›

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) reached a new 52-week high on Friday after Guggenheim Securities upgraded the stock and raised its price target. The biotechnology company's stock traded as high as $11.49 before closing at $10.90, up nearly 4% on the day.

Why it matters

Relay Therapeutics is a clinical-stage biotech focused on developing precision therapies for cancer. The positive analyst coverage and stock price surge indicate growing investor confidence in the company's drug discovery platform and pipeline, which leverages computational modeling and structural biology to identify promising drug candidates.

The details

Guggenheim upgraded Relay Therapeutics to a 'buy' rating and increased its price target from $15 to $22 per share. The firm cited the company's progress in advancing its drug candidates through clinical trials. Relay Therapeutics also received positive ratings from other analysts, with one 'strong buy', four 'buy', and one 'sell' recommendation.

  • Relay Therapeutics' stock reached a new 52-week high of $11.49 on March 13, 2026.
  • Guggenheim raised its price target on Relay Therapeutics on March 13, 2026.

The players

Relay Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing precision therapies for cancer using computational modeling and structural biology.

Guggenheim

An investment bank and financial services firm that provides research coverage and analysis on Relay Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The surge in Relay Therapeutics' stock price following the Guggenheim upgrade highlights growing investor optimism around the company's innovative drug discovery platform and its potential to develop effective cancer treatments. This momentum could signal further upside for the biotech firm as it continues advancing its pipeline.